- Lobbying
- Lobbying by Amgen Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Dave Boyer | Sp Asst to Sec HHS, Con Asst, Off of WH Liaison DoD Sp Asst Pres LA, Asst Comm Leg, FDA See prior filing |
Robert Wood | Chief of Staff to HHS Secretary See prior filing Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug |
Ryan Long | See prior filing LC Rep Norwood; LA & LD Rep Barton; Prof. Staff, Csel, & Chief Csel Hse E&C Ctme |
Brent Del Monte | See prior filing LA/LD Rep. Tom Bliley; Counsel House Energy & Commerce Committee Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee |
Robb Walton | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi See prior filing Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes |
Daniel Murphy | COS Sec of HUD |
Jennifer Larkin Lukawski | See prior filing Leg. Dir. Rep. Dornan, Ex. Dir. Hs. Con. Ac. Team |
Dan Murphy | See prior filing Chief of Staff to HUD Secretary |
John Stone | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel,House E&C Ctme Health Subcommittee See prior filing Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C |
Matthew Hoffmann | St. Asst. Rep. Vitter; LC Rep. Vitter; Sen. LC .Rep. Vitter; LA Rep. Paul Ryan; Sen. LA Rep. Paul Ryan; LD Rep. Paul Ryan; Budget Analyst Rep. Paul Ryan; St. Dir. Health Subcmte House W&M Cmte; Policy Analyst Off. Speaker; Policy Dir. Sen. Fin Cmte. See prior filing |
Remy Brim | Senior FDA Policy Advisor to the Senate HELP Committee Ranking Member, Sen. Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz |
Daniel Farmer | St. Asst Rep. Debbie Wasserman Schultz; Leg. Corr. Rep. Debbie Wasserman Schultz; Leg. Corr./Leg. Asst. Rep. Debbie Wasserman Schultz; Leg. Asst. Rep. Zack Space; Sr. Leg. Asst. Rep. Zack Space; Leg. Dir. Zack Space See prior filing Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space |
Joel Bailey | COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA / Sr. LA Rep. Baron Hill See prior filing COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall |
Raghav Aggarwal | Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers..
Registration
Issue(s) they said they’d lobby about: Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate